Bradykinin

Overview

Bradykinin is a 9-amino-acid vasoactive peptide generated by the kallikrein-kinin system (KKS), one of the oldest recognized proteolytic cascade systems in mammalian physiology. The name derives from the Greek "bradys" (slow) and "kinein" (to move), reflecting the slow, sustained contraction of guinea pig ileum observed in the original bioassay by Mauricio Rocha e Silva, Wilson Beraldo, and Gastao Rosenfeld in 1949.

Bradykinin is produced through the enzymatic cleavage of high-molecular-weight kininogen (HMWK) by plasma kallikrein in the kinin-kallikrein system, and of low-molecular-weight kininogen (LMWK) by tissue kallikrein (the latter generating kallidin/Lys-bradykinin, which is subsequently converted to bradykinin by aminopeptidases). Once generated, bradykinin acts on two receptor subtypes — B1 and B2 — to produce vasodilation, increased vascular permeability, pain sensitization, and smooth muscle contraction.

The peptide has broad clinical significance:

• ACE inhibitor pharmacology — Angiotensin-converting enzyme (ACE) is the principal degradation enzyme for bradykinin. ACE inhibitors elevate bradykinin levels, contributing both to their beneficial cardiovascular effects and to the side effects of dry cough and angioedema
• Hereditary angioedema (HAE) — Deficiency of C1-inhibitor leads to excessive bradykinin generation and episodic life-threatening swelling; B2 receptor antagonists (icatibant) provide acute treatment
• Inflammatory and pain signaling — Bradykinin is one of the most potent endogenous algogenic (pain-producing) substances, sensitizing nociceptors to subsequent stimuli

Bradykinin operates at the intersection of coagulation, inflammation, and vascular physiology, and its biological effects are typically rapid, potent, and transient due to extremely rapid enzymatic degradation.

Structure and Sequence

Bradykinin is a linear nonapeptide:

Sequence: Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg

• Molecular weight: 1,060.2 g/mol
• Molecular formula: C50H73N15O11
• Key structural features:
  • Arginine bookends: Arg1 and Arg9 are critical for B2 receptor binding
  • Proline residues: Three prolines (positions 2, 3, 7) confer rigidity to the peptide backbone and create characteristic beta-turns
  • Phenylalanine residues: Phe5 and Phe8 are important for receptor activation
  • No disulfide bonds or post-translational modifications: The peptide is a simple, unmodified linear chain
  • Beta-turn structure: The Pro2-Pro3-Gly4-Phe5 segment adopts a type II beta-turn that is important for receptor recognition

Related kinins:

• Kallidin (Lys-bradykinin): Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg — the decapeptide generated by tissue kallikrein
• Des-Arg9-bradykinin: Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe — the C-terminal truncation product that is the preferred ligand for B1 receptors

Mechanism of Action

Receptor Pharmacology

Bradykinin signals through two G-protein coupled receptors:

B2 receptor (constitutive):

• Constitutively expressed on endothelium, smooth muscle, sensory neurons, and epithelial cells
• Primary receptor for intact bradykinin and kallidin
• Coupled to Gq proteins: activates phospholipase C, increases intracellular calcium, and stimulates inositol trisphosphate (IP3) production
• Stimulates endothelial nitric oxide synthase (eNOS) and prostacyclin (PGI2) production, mediating vasodilation
• Rapidly desensitized upon sustained agonist exposure through receptor internalization

B1 receptor (inducible):

• Minimally expressed under basal conditions; markedly upregulated by tissue injury, inflammation, and cytokines (IL-1beta, TNF-alpha)
• Preferred ligand is des-Arg9-bradykinin (the carboxypeptidase-generated metabolite)
• Coupled to Gq proteins with similar downstream signaling to B2
• Does not undergo rapid desensitization, allowing sustained signaling during chronic inflammation
• Considered a mediator of chronic inflammatory pain

Vascular Effects

Bradykinin produces vasodilation primarily through endothelium-dependent mechanisms:

1. B2 receptor activation on endothelial cells stimulates eNOS, producing nitric oxide (NO)
2. Concurrent activation of phospholipase A2 generates arachidonic acid metabolites, particularly prostacyclin
3. Endothelium-derived hyperpolarizing factor (EDHF) contributes to vasodilation in some vascular beds
4. Increased vascular permeability through contraction of endothelial cells and opening of intercellular gaps

Pain and Nociception

Bradykinin is one of the most potent endogenous pain-producing substances:

• Direct activation of B2 receptors on sensory nerve endings triggers nociceptor firing
• Sensitization of TRPV1 (capsaicin) channels through PKC-mediated phosphorylation lowers the thermal pain threshold
• Release of prostaglandins and substance P amplifies nociceptive signaling
• B1 receptor upregulation during chronic inflammation contributes to persistent pain states

The Kallikrein-Kinin Cascade

Bradykinin generation is tightly regulated:

1. Factor XII (Hageman factor) is activated by contact with negatively charged surfaces
2. Activated Factor XII converts prekallikrein to plasma kallikrein
3. Plasma kallikrein cleaves HMWK to release bradykinin
4. Bradykinin is rapidly degraded by ACE (kininase II), carboxypeptidase N, neprilysin, and aminopeptidase P

Research Summary

Pharmacokinetics

• Plasma half-life: approximately 15-30 seconds; one of the shortest-lived bioactive peptides in circulation
• Primary degradation enzymes: ACE (kininase II) cleaves the Pro7-Phe8 bond; carboxypeptidase N removes C-terminal Arg9 to generate des-Arg9-BK; neprilysin and aminopeptidase P provide additional degradation
• Generation: plasma kallikrein from HMWK (blood); tissue kallikrein from LMWK (tissues, generating kallidin first)
• Site of action: predominantly paracrine and autocrine; generated and degraded locally at sites of tissue injury
• Blood levels: essentially undetectable under normal conditions due to rapid degradation; measurable only with specialized rapid-processing assays
• ACE inhibitor effect: ACE inhibition increases bradykinin levels approximately 2-5 fold, extending its effective half-life

Common Discussion Topics

ACE Inhibitors and the Bradykinin Connection

The clinical pharmacology of ACE inhibitors cannot be fully understood without considering bradykinin. While these drugs are prescribed primarily for their suppression of angiotensin II production, ACE (also known as kininase II) is simultaneously the principal degradation enzyme for bradykinin. The resulting elevation in bradykinin contributes to vasodilation, cardioprotection, and the anti-remodeling effects of ACE inhibitors. Conversely, bradykinin accumulation accounts for the dry, non-productive cough that affects 5-20% of patients (more common in East Asian populations due to genetic variation in bradykinin metabolism) and the rare but serious complication of angioedema.

Hereditary Angioedema

Hereditary angioedema (HAE) is caused by deficiency or dysfunction of C1-inhibitor (C1-INH), a serine protease inhibitor that normally regulates plasma kallikrein and Factor XII. C1-INH deficiency leads to uncontrolled kallikrein activity and excessive bradykinin generation, producing episodic subcutaneous and submucosal swelling. Laryngeal involvement can be life-threatening. The identification of bradykinin as the mediator of HAE swelling (rather than complement-derived mediators as previously assumed) led to the development of targeted therapies including icatibant (B2 antagonist), ecallantide (kallikrein inhibitor), and lanadelumab (anti-kallikrein monoclonal antibody).

Bradykinin in the COVID-19 Pandemic

During the COVID-19 pandemic, a computational analysis proposed that SARS-CoV-2 infection dysregulates the bradykinin system through upregulation of bradykinin-producing enzymes and downregulation of degradation pathways, creating a "bradykinin storm" in the lungs. This hypothesis attempted to explain the observed pulmonary edema, vascular leakage, and inflammatory changes in severe COVID-19. While the hypothesis generated considerable attention, direct clinical validation has been limited.

Interactions with Prostaglandin and Nitric Oxide Systems

Bradykinin's vascular effects are substantially mediated through secondary messenger release rather than direct smooth muscle action. The peptide's ability to simultaneously activate nitric oxide, prostacyclin, and EDHF pathways places it at a convergence point of multiple vasodilatory mechanisms. This interaction has implications for understanding how NSAIDs (which block prostaglandin synthesis) may partially attenuate bradykinin-mediated vascular effects.

Dosing Protocols

As an endogenous vasoactive peptide, bradykinin is not typically administered exogenously in clinical practice. It is primarily studied as a mediator in pain signaling, inflammation, and vascular permeability, or through receptor-targeted interventions. The therapeutic relevance of bradykinin biology is realized through its antagonist icatibant (Firazyr) for hereditary angioedema and through ACE inhibitors, which reduce bradykinin degradation to achieve their antihypertensive and cardioprotective effects.

Related Compounds

• CGRP — A potent vasodilatory neuropeptide with complementary roles in pain signaling and vascular regulation
• BNP — A cardiac natriuretic peptide with vasodilatory properties acting through distinct cyclic GMP-mediated pathways
• Endothelin-1 — A potent vasoconstrictor whose actions functionally oppose bradykinin-mediated vasodilation
• VIP — A vasodilatory neuropeptide with overlapping anti-inflammatory and smooth muscle-relaxant properties